Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 1

Patients could have to wait up to two years longer to access new cancer drugs after the UK leaves the EU as drug companies will prioritise winning approval for access to the larger European market over the UK, experts have warned.

Sir Alasdair Breckenridge has warned that drug companies will prioritise application to the European Medicines Agency over the UK regulator because the UK market is much smaller

Source